Prosecution Insights
Last updated: April 19, 2026
Application No. 17/744,614

ANTIGENIC NEURON SPECIFIC ENOLASE PEPTIDES FOR DIAGNOSING AND TREATING AUTISM

Final Rejection §101
Filed
May 13, 2022
Examiner
CHERNYSHEV, OLGA N
Art Unit
1675
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of California
OA Round
2 (Final)
54%
Grant Probability
Moderate
3-4
OA Rounds
3y 2m
To Grant
89%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allow Rate
512 granted / 942 resolved
-5.6% vs TC avg
Strong +34% interview lift
Without
With
+34.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
44 currently pending
Career history
986
Total Applications
across all art units

Statute-Specific Performance

§101
14.8%
-25.2% vs TC avg
§103
8.6%
-31.4% vs TC avg
§102
12.6%
-27.4% vs TC avg
§112
45.6%
+5.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 942 resolved cases

Office Action

§101
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Response to Amendment 1. Claims 1-4, 7, 8 and 10 have been amended, claims 6 and 11-19 canceled and claims 20-23 added as requested in the amendment filed on January 02, 2026. Following the amendment, claims 1-5, 7-10 and 20-23 are pending in the instant application. 2. Claims 1-5, 7-10 and 20-23 are under examination in the instant office action. 3. Any objection or rejection of record, which is not expressly repeated in this action has been overcome by Applicant’s response and withdrawn. 4. Applicant’s arguments filed on January 02, 2026 have been fully considered but found to be not persuasive for reasons set forth below. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. 5. Claims 8-10 and new claims 20-21 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception (i.e., a law of nature, a natural phenomenon, or an abstract idea) without significantly more, see reasons of record in section 5 of Paper mailed on October 03, 2025. Applicant argues at p. 5 of the Response that the claims have been amended to indicate that the claimed peptides comprise a label. While this has been fully considered, the evidence suggests otherwise as the peptides within the composition of claims 8-10 as well as new claims 20 and 21 do not recite a label. For reasons of record fully explained earlier and reasons above, the rejection is maintained. Conclusion 6. Claims 1-5 and 7 are allowed. Claims 8-10, 20 and 21 are rejected. Claim22 and 23 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. 7. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to OLGA N CHERNYSHEV whose telephone number is (571)272-0870. The examiner can normally be reached 9AM to 5:30PM, Monday to Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at (571)272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /OLGA N CHERNYSHEV/ Primary Examiner, Art Unit 1675 March 7, 2026
Read full office action

Prosecution Timeline

May 13, 2022
Application Filed
Oct 02, 2025
Non-Final Rejection — §101
Jan 02, 2026
Response Filed
Mar 08, 2026
Final Rejection — §101 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12601750
DIAGNOSING MILD COGNITIVE IMPAIRMENT (MCI), PREDICTING ALZHEIMER'S DISEASE (AD) DEMENTIA ONSET, AND SCREENING AND MONITORING AGENTS FOR TREATING MCI OR PREVENTING DEMENTIA ONSET
2y 5m to grant Granted Apr 14, 2026
Patent 12601751
PROTEIN ANTIGEN COMBINATION FOR DETECTION OF ALZHEIMER'S DISEASE AND APPLICATION THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12596126
METHODS FOR THE PREDICTION, PROGNOSIS, AND/OR DIAGNOSIS OF AN INFLAMMATORY RESPONSE ASSOCIATED WITH SCHIZOPHRENIA
2y 5m to grant Granted Apr 07, 2026
Patent 12589098
METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENER
2y 5m to grant Granted Mar 31, 2026
Patent 12582693
GLUTATHIONE TRISULFIDE (GSSSG) IN NEUROPROTECTION
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
54%
Grant Probability
89%
With Interview (+34.4%)
3y 2m
Median Time to Grant
Moderate
PTA Risk
Based on 942 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month